Lack of apoptosis in panIN-1 and PanIN-2 lesions associated with pancreatic ductal adenocarcinoma is not dependent on K-ras status

Pancreas

Volumn 27, Issue 3, 2003, Pages

  Lüttges, Jutta ^a   Neumann, Svenja ^a   Jesnowski, Ralf ^b   Borries, Vivian ^a   Löhr, Matthias ^b   Klüppel, Günter ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF MANNHEIM   (Germany)

Author keywords

Apoptosis; Bcl 2; K ras mutation; P53; Pancreatic ductal carcinoma; PanIN

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; ARTICLE; CELL DIVISION; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; ONCOGENE RAS; PANCREAS CARCINOMA; PANCREAS DUCT; PANCREAS TUMOR; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL DIVISION; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREATIC DUCTS; PANCREATIC NEOPLASMS;

EID: 1542646285     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/00006676-200310000-00021     Document Type: Article

References (42)

1. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996; 271:350-353.
2. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, et al. Molecular pathology of pancreatic cancer. Cancer J. 2001; 7:251-258.
3. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 1997; 57:2140-2143.
4. Klöppel G, Hruban RH, Longnecker DS, et al. Ductal adenocarcinoma of the pancreas. In: Hamilton SR, Aaltonen LA, eds. Pathology and Genetics of Tumours of the Digestive System. WHO Classification of Tumours. Lyon: IARC Press, 2000:221-230.
5. Heinmöller E, Dietmaier W, Zirngibl H, et al. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol. 2000; 157:83-92.
6. Yamano M, Fujii H, Takagaki T, et al. Genetic progression and divergence in pancreatic carcinoma. Am J Pathol. 2000; 156:2123-2133.
7. Lüttges J, Galehdari H, Bröcker V, et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol. 2001; 158:1677-1683.
8. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia. A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001; 25:579-586.
9. Pour PM, Sayed S, Sayed G. Hyperplastic, preneoplastic and neoplastic lesions found in 83 human pancreases. Am J Clin Pathol. 1982; 77:137-152.
10. Tada M, Ohashi M, Shiratori Y, et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology. 1996; 110:227-231.
11. Lüttges J, Schlehe B, Menke MAOH, et al. The K-ras mutation pattern in pancreatic ductal adenocarcinoma is usually identical to that in associated normal, hyperplastic and metaplastic duct epithelium. Cancer. 1999; 85:1703-1710.
12. Berger DH, Chang H, Wood M, et al. Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status. Cancer. 1999; 85:326-332.
13. Reed JC. Mechanisms of apoptosis. Am J Pathol. 2000; 157:1415-1430.
14. Chen CY, Faller DV. Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene. 1995; 11:1487-1498.
15. Klein WM, Hruban RH, Klein-Szanto AJP, et al. Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol. 2002; 15:441-447.
16. Lu QL, Abel P, Foster CS, et al. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol. 1996; 27:102-110.
17. Lüttges J, Vogel I, Menke M, et al. The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Arch. 1998; 433:237-242.
18. Lüttges J, Schemm S, Vogel I, et al. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol. 2000; 191:154-161.
19. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 1995; 146:3-15.
20. Lüttges J, Reinecke-Lüthge A, Möllmann B, et al. Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. Virchows Arch. 1999; 435:461-468.
21. Bühl A, Zöfel P. SPSS für Windows, Version 6.1. Praxisorientierte Einführung in die moderne Datenanalyse. Bonn: Addison-Wesley, 1996.
22. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988; 53:549-554.
23. Matsubayashi H, Watanabe H, Nishikura K, et al. Determination of pancreatic ductal carcinoma histogenesis by analysis of mucous quality and K-ras mutation. Cancer. 1998; 82:651-660.
24. Tabata T, Fujimoro T, Maeda S, et al. The role of ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis. Int J Pancreatol. 1993; 14:237-244.
25. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989; 49:4682-4689.
26. Shaw PH. The role of p53 in cell cycle regulation. Pathol Res Pract. 1996; 192:669-675.
27. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996; 88:386-401.
28. Cip1/WAF/Sdi1. J Pathol. 1997; 183:134-140.
29. Khosravi-Far R, Campbell S, Rossman KL, et al. Increasing complexity of ras signal transduction: Involvement of rho family proteins. Adv Cancer Res. 1998; 72:57-107.
30. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997; 57:3126-3130.
31. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996; 56:5360-5364.
32. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol. 2000; 156:1767-1771.
33. Ward RL, Todd AV, Santiago F, et al. Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer. 1997; 79:1106-1113.
34. Lipponen P, Aaltomaa S, Kosma VM, et al. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer. 1994; 30A:2068-2073.
35. Zhang GJ, Kimijima I, Abe R, et al. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res. 1998; 18:1989-1998.
36. Shen KL, Harn HJ, Ho LI, et al. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling. Cancer. 1998; 82:2373-2381.
37. Shiina H, Igawa M, Shigeno K, et al. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology. 1999; 56:239-247.
38. Wang LD, Zhou Q, Yang WC, et al. Apoptosis and cell proliferation in esophageal precancerous and cancerous lesions: study of a high-risk population in northern China. Anticancer Res. 1999; 19:369-374.
39. Nio Y, Iguchi C, Yamasawa K, et al. Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas. Pancreas. 2001; 22:230-239.
40. Virkajärvi N, Päkkö P, Soini Y. Apoptotic index and apoptosis influencing proteins bcl-2, mcl-1, bax and caspases 3, 6 and 8 in pancreatic carcinoma. Histopathology. 1998; 33:432-439.
41. Campani D, Esposito I, Boggi U, et al. Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol. 2001; 194:444-450.
42. Friess H, Lu Z, Graber HU, et al. bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut. 1998; 43:414-421.